exRNAdisease

General Information

Database ID:

exR0084138

RNA Name:

USP22

RNA Type:

mRNA

Chromosome:

chr17

Starnd:

Coordinate:

Start Site(bp):

20999596

End Site(bp):

21043760

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AARS2	chr6	44298731	44313347	-
ABCB1	chr7	87503017	87713323	-
AC005726.1	chr17	28455752	28614185	-
AC008581.2	chr5	77030902	77152155	+
AC008695.1	chr5	131425891	131796983	-
AC010422.3	chr19	12643831	12648397	-
AC138811.2	chr16	18788063	18801519	-
ACBD3	chr1	226144679	226186741	-
ACIN1	chr14	23058564	23095614	-
ACLY	chr17	41866917	41930542	-
ADH5	chr4	99070978	99088801	-
ADSL	chr22	40346500	40390463	+
AGGF1	chr5	77029251	77065234	+
AHCY	chr20	34280268	34311802	-
AKR1B1	chr7	134442356	134459284	-
AL022238.4	chr22	40346529	40410054	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-148b-3p	chr12	54337278	54337299	+
hsa-miR-485-5p	chr14	101055427	101055448	+
hsa-miR-650	chr22	22822791	22822811	+
hsa-miR-371a-5p	chr19	53787680	53787699	+
hsa-miR-616-3p	chr12	57519183	57519204	-
hsa-miR-665	chr14	100875075	100875094	+
hsa-miR-1321	chrX	85835832	85835849	+
hsa-miR-4508	chr15	23562107	23562123	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC006064.5	chr12	6510275	6510522	+
AC007952.4	chr17	19112000	19112636	-
AC011445.1	chr19	39314651	39320858	-
AC016876.2	chr17	7581964	7584086	-
AC026362.1	chr12	122975320	122982907	+
AC067852.1	chr17	42536510	42562062	+
AC067930.1	chr8	143579636	143580670	+
AC087190.3	chr16	9104848	9113181	+
AC111170.2	chr17	77469162	77472770	-
AC133644.3	chr2	87455476	87767359	+
AD000090.1	chr19	35557956	35581954	+
AL022311.1	chr22	37876148	37895563	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference